GlassScriptPhysician profile
Diana Roy
NPI 1609403047
$1,436.79
in general payments reported to CMS, 2019-2025
22 companies · $449 in 2025
The $449 reported for 2025 was more than what 77% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $11.21 · 2023: $147 · 2024: $830 · 2025: $449.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,426.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,425.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $316.36 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $197.06 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $197.01 | 2023-2025 | Farxiga, Breztri, Airsupra |
| Exact Sciences Corporation | $77.36 | 2024-2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $63.36 | 2024-2025 | Zepbound, Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $63.27 | 2024-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $57.04 | 2024 | Spravato |
| Bayer Healthcare Pharmaceuticals INC. | $54.64 | 2024-2025 | |
| Eisai INC. | $53.53 | 2024-2025 | |
| Astellas Pharma US INC | $49.91 | 2024-2025 | Veozah |
| Dexcom, INC. | $44.92 | 2024-2025 | Dexcom G6 Transmitter |
| Idorsia Pharmaceuticals US INC | $38.39 | 2023-2024 | Quviviq |
| Antares Pharma, INC. | $37.05 | 2024 | Xyosted |
| Glaxosmithkline, LLC. | $28.65 | 2023-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Axsome Therapeutics, INC. | $25.17 | 2024 | Auvelity |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $23.00 | 2022-2023 | Nexplanon |
| Recor Medical INC | $20.60 | 2025 | Paradise Ultrasound Renal Denervation System |
| Lundbeck LLC | $20.50 | 2023 | Vyepti |
| Travere Therapeutics, INC. | $19.46 | 2023 | |
| Dynavax Technologies Corporation | $18.07 | 2025 | Heplisav-B |
| Pfizer INC. | $16.26 | 2025 | |
| Kyowa Kirin, INC. | $15.18 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diana Roy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.